Economy Enters 2025 on Strong Footing as Markets Digest Policy Uncertainty
Tempus AI (NASDAQ: TEM) and Genialis have announced a multi-year collaboration to develop new RNA-based algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate their AI foundation model, the Genialis™ Supermodel, which was developed using ~1 million RNA-sequencing samples.
Through this partnership, Genialis gains access to Tempus' Lens analytics platform, providing de-identified multimodal patient records to validate biomarker signatures. Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for their xR platform.
The collaboration has already yielded results with Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' data, effectively stratifies patients into response groups based on their likelihood of treatment success.
Tempus AI (NASDAQ: TEM) e Genialis hanno annunciato una collaborazione pluriennale per sviluppare nuovi algoritmi basati su RNA per il trattamento del cancro. Genialis utilizzerà il dataset multimodale di Tempus per convalidare il loro modello fondazionale di intelligenza artificiale, il Genialis™ Supermodel, sviluppato utilizzando circa 1 milione di campioni di sequenziamento RNA.
Grazie a questa partnership, Genialis ottiene accesso alla piattaforma di analisi Lens di Tempus, che fornisce registri pazienti multimodali de-identificati per convalidare le firme dei biomarcatori. Tempus riceve i diritti per valutare e potenzialmente licenziare gli algoritmi sviluppati da Genialis per la loro piattaforma xR.
La collaborazione ha già prodotto risultati con Genialis™krasID, il primo algoritmo commerciale che prevede la risposta dei pazienti alle terapie mirate contro KRAS in diversi tipi di cancro. Questo algoritmo, convalidato utilizzando i dati di Tempus, stratifica efficacemente i pazienti in gruppi di risposta in base alla loro probabilità di successo del trattamento.
Tempus AI (NASDAQ: TEM) y Genialis han anunciado una colaboración por varios años para desarrollar nuevos algoritmos basados en RNA para el tratamiento del cáncer. Genialis utilizará el conjunto de datos multimodal de Tempus para validar su modelo base de inteligencia artificial, el Genialis™ Supermodel, que fue desarrollado utilizando aproximadamente 1 millón de muestras de secuenciación de RNA.
A través de esta asociación, Genialis obtiene acceso a la plataforma de análisis Lens de Tempus, que proporciona registros de pacientes multimodales desidentificados para validar las firmas de biomarcadores. Tempus recibe derechos para evaluar y potencialmente licenciar los algoritmos desarrollados por Genialis para su plataforma xR.
La colaboración ya ha producido resultados con Genialis™krasID, el primer algoritmo comercial que predice la respuesta de los pacientes a las terapias dirigidas contra KRAS en diferentes tipos de cáncer. Este algoritmo, validado utilizando los datos de Tempus, estratifica eficazmente a los pacientes en grupos de respuesta según su probabilidad de éxito en el tratamiento.
템퍼스 AI (NASDAQ: TEM)와 제날리스가 암 치료를 위한 새로운 RNA 기반 알고리즘 개발을 위한 다년간 협력 관계를 발표했습니다. 제날리스는 약 100만 개의 RNA 시퀀싱 샘플을 사용하여 개발된 AI 기반 모델인 Genialis™ Supermodel을 검증하기 위해 템퍼스의 다중 모달 데이터 세트를 활용할 것입니다.
이 파트너십을 통해 제날리스는 템퍼스의 렌즈 분석 플랫폼에 접근하여 바이오마커 서명을 검증하기 위해 비식별화된 다중 모달 환자 기록을 제공합니다. 템퍼스는 제날리스가 개발한 알고리즘을 평가하고 잠재적으로 xR 플랫폼에 라이선스를 부여할 권리를 받습니다.
이 협력은 이미 제날리스™krasID와 같은 결과를 낳았으며, 이는 다양한 암 유형에 대한 KRAS 표적 치료에 대한 환자의 반응을 예측하는 첫 상업적 알고리즘입니다. 이 알고리즘은 템퍼스의 데이터를 사용하여 검증되었으며, 치료 성공 가능성에 따라 환자를 반응 그룹으로 효과적으로 분류합니다.
Tempus AI (NASDAQ: TEM) et Genialis ont annoncé une collaboration pluriannuelle pour développer de nouveaux algorithmes basés sur l'ARN pour le traitement du cancer. Genialis utilisera le jeu de données multimodal de Tempus pour valider leur modèle fondamental d'intelligence artificielle, le Genialis™ Supermodel, qui a été développé en utilisant environ 1 million d'échantillons de séquençage d'ARN.
Grâce à ce partenariat, Genialis a accès à la plateforme d'analyse Lens de Tempus, fournissant des dossiers patients multimodaux désidentifiés pour valider les signatures de biomarqueurs. Tempus reçoit des droits pour évaluer et potentiellement accorder une licence aux algorithmes développés par Genialis pour leur plateforme xR.
La collaboration a déjà produit des résultats avec Genialis™krasID, le premier algorithme commercial prédisant la réponse des patients aux thérapies ciblées KRAS dans différents types de cancer. Cet algorithme, validé à l'aide des données de Tempus, stratifie efficacement les patients en groupes de réponse en fonction de leur probabilité de succès du traitement.
Tempus AI (NASDAQ: TEM) und Genialis haben eine mehrjährige Zusammenarbeit zur Entwicklung neuer RNA-basierter Algorithmen zur Krebsbehandlung angekündigt. Genialis wird das multimodale Datenset von Tempus nutzen, um ihr KI-Grundlagenmodell, das Genialis™ Supermodel, zu validieren, das mit etwa 1 Million RNA-Sequenzierungsproben entwickelt wurde.
Durch diese Partnerschaft erhält Genialis Zugang zur Lens-Analytik-Plattform von Tempus, die anonymisierte multimodale Patientenakten bereitstellt, um Biomarker-Signaturen zu validieren. Tempus erhält das Recht, die von Genialis entwickelten Algorithmen für ihre xR-Plattform zu bewerten und möglicherweise zu lizenzieren.
Die Zusammenarbeit hat bereits Ergebnisse hervorgebracht, darunter Genialis™krasID, den ersten kommerziellen Algorithmus, der die Patientenreaktion auf KRAS-zielgerichtete Therapien über verschiedene Krebsarten hinweg vorhersagt. Dieser Algorithmus, der mit den Daten von Tempus validiert wurde, stratifiziert Patienten effektiv in Reaktionsgruppen basierend auf ihrer Wahrscheinlichkeit des Behandlungserfolgs.
- Strategic access to Tempus' extensive multimodal dataset for algorithm validation
- Successful launch of Genialis™krasID commercial algorithm
- Potential revenue stream from algorithm licensing for Tempus
- Validated clinical utility in real-world studies
- None.
Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment. To address this, Genialis has developed an AI foundation model using data from ~1 million RNA-sequencing samples representing globally diverse patients. This large molecular model (LMM), dubbed the Genialis TM Supermodel, yields accurate and information-rich biomarker algorithms to help biopharma improve therapeutic development. Validating Genialis’ LMM using Tempus real-world multi-modal data is essential to demonstrate the clinical utility and broad applicability of these biomarkers in drug development and clinical practice. As part of the collaboration, Genialis can now leverage Tempus’ analytics platform, Lens, which provides a development platform accessing de-identified multimodal patient records and a suite of tools to validate signatures to accelerate the company’s efforts to bring its clinical algorithms to market. In return, Tempus gains the right to evaluate and potentially license Genialis-developed algorithms for commercialization as a component of the xR platform.
Tempus multimodal dataset has already proved pivotal in the launch of Genialis™krasID, the first commercially available algorithm that stratifies patients who benefit from KRAS inhibition. Presented at the 6th Annual Targeting-RAS Drug Development Summit in September 2024, Genialis krasID uniquely predicts patient response to KRAS-targeted therapies across cancer types and driver mutations. Independently validated using Tempus’ real-world data, Genialis krasID stratifies patients into high and low likelihood response groups that have been evaluated in real-world studies1,2.
“We look forward to working with Genialis and demonstrating new ways in which our data can be applied to further a new kind of research, one that embraces the power that RNA-based biomarkers can have on the future of cancer care,” said Kate Sasser, Ph.D., Chief Scientific Officer at Tempus. “Multimodal algorithms, including RNA signatures, are demonstrating rapid advancement in clinical utility for personalized treatment decisions, and we are excited to partner with Genialis to fuel this data-driven precision medicine future with our xR assay and vast multimodal dataset.”
“Biomarkers have the potential to transform how cancer is diagnosed and treated, but today’s standard of care leaves a lot to be desired in terms of accuracy, information richness, and patient reach,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “With this strategic agreement with Tempus, Genialis will have access to an unparalleled data resource to validate our cutting-edge patient classifiers.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of the collaboration with Genialis in developing biomarker algorithms, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
About Genialis
Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit www.genialis.com
1 Žiberna, et al. (2024). Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy. Presented at the American Association for Cancer Research (AACR) Annual Meeting. Retrieved from https://www.genialis.com/2024/04/09/genialis-krasid-biology-driven-machine-learning-to-personalize-kras-inhibitor-therapy/
2 Žiberna, et al. (2024). krasID at RAS Drug Development Summit. Poster presented at the RAS Drug Development Summit, American Association for Cancer Research (AACR). Retrieved from https://www.genialis.com/2024/09/25/genialis-krasid-biology-driven-machine-learning-to-personalize-kras-inhibitor-therapy-2/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108867515/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What is the purpose of the Tempus AI (TEM) and Genialis collaboration?
How many RNA-sequencing samples were used in Genialis' AI foundation model?
What is Genialis™krasID and what does it do?
What access does Genialis gain through the Tempus (TEM) partnership?
What rights does Tempus (TEM) receive in the collaboration with Genialis?
